Tagged with Clinical Trials

Saudi Arabia Mohamed Fawzy, Country President for Pfizer Saudi Arabia, discusses the company’s evolving role in supporting the Kingdom’s rapidly transforming healthcare sector. He shares insights on Pfizer’s local footprint, its contributions to public health through innovative vaccines and oncology treatments, and the company’s commitment to talent development and localization. Fawzy also…

Mexico Mexico has long been considered a relatively appealing destination for clinical trials and, in recent years, has participated in more than one percent of global drug development research, generating an economic outflow of over 240 million dollars per annum in the process. Indeed, most of the major biopharma multinationals now…

Saudi Arabia Saudi Arabia is rapidly shaping its future as a global research powerhouse, channelling unprecedented resources into translational research, clinical trials, and genomics. At the heart of this transformation is the Saudi NIH, driving 13 key research priorities and forging strategic global partnerships. Speaking at The Global Healthspan Summit (GHS 2025)…

Puerto Rico Could the future of metastatic cancer treatment lie in a groundbreaking compound developed in Puerto Rico? Dr. José F. Rodriguez-Orengo, CEO of MBQ Pharma, leads the development of MBQ-167, a first-in-class therapy designed to disrupt cancer progression. As the company navigates challenges in funding, it is also paving the way…

Europe James Riddle of Advarra, writing in the January 2025 edition of DIA’s Global Forum magazine, looks at how the EU’s AI Regulation will impact clinical trials in Europe.   In an era where artificial intelligence (AI) is revolutionizing healthcare and clinical research, regulatory bodies are racing to keep pace. The…

China Dr Yingjia Zhang and Simon Hua of leading China-based CRO Biometas delve into the company’s rapid expansion in the preclinical space, strategic growth plans, and its positioning in the global CRO market. Focused on both organic growth and potential acquisitions, Biometas is leveraging a strong client base in the US…

Mexico Monica Palomanes, General Manager of Roche Mexico, discusses her journey within the company and the shift from traditional sales to a collaborative approach with Patient Journey Partners. She addresses challenges in access and diagnosis within Mexico’s fragmented healthcare system, while recognising the country’s potential for clinical research due to the…

Global Almost 2,500 attendees flocked to Madrid last week for the 2024 edition of Clinical Trials on Alzheimer’s Disease (CTAD). The first European edition of the conference since 2018 was punctuated by a mood of excitement, with Leqembi (lecanemab) – the second drug that targets Alzheimer’s disease progression by reducing amyloid…

Puerto Rico The Puerto Rico Consortium for Clinical Investigation (PRCCI) is a non-profit organisation offering specialised clinical trials services. Executive director Dr Amarilys Silva-Boschetti shares key developments since she last spoke with PharmaBoardroom in 2020, including the creation of a new clinical research centre with trials set to begin in 2024 and…

Mexico Cecilia Moreno, from the PPD™ clinical research business of Thermo Fisher Scientific, highlights Mexico’s growing role in clinical research, supported by regulatory advancements and a skilled workforce. Moreno emphasizes the potential for expanding clinical trials in Mexico, enhancing patient access to innovative therapies, and leveraging the country’s strategic advantages in…

Mexico Arturo Rodriguez, CEO of Infinite Clinical Research, discusses the current state of clinical trials in Mexico and highlights the country’s unique advantages, such as a diverse population with experienced medical professionals and top-notch medical facilities. He addresses the challenges of streamlining regulatory processes and the need for improvements to attract…

Switzerland Kari Sarvanto outlines his journey from leading PRIMEX to establishing CRAB, a preclinical oncology company focused on non-toxic cancer treatments. Sarvanto highlights his strategic leadership background, the innovative approach of targeting metabolic dysfunctions in cancer, and the promising progress of their lead drug, CRB091, particularly in treating aggressive cancers like…